Indivior Pharmaceuticals, Inc. (INDV)
About Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.2B
- Net income
- $210.0M
- Total assets
- $1.2B
- Market cap
- $4.4B
- Gross margin
- 80.2%
- Operating margin
- 21.1%
- Net margin
- 16.9%
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $1.2B
- Cost of revenue
- $246.0M
- Gross profit
- $994.0M
- Operating expenses
- $732.0M
- Operating income
- $262.0M
- Income tax
- $29.0M
- Net income
- $210.0M
- EPS (basic)
- $1.68
- EPS (diluted)
- $1.64
Balance sheet
- Total assets
- $1.2B
- Current assets
- $652.0M
- Total liabilities
- $1.3B
- Current liabilities
- $914.0M
- Shareholders’ equity
- -$98.0M
Cash flow
- Operating cash flow
- -$27.0M
- Investing cash flow
- -$66.0M
- Financing cash flow
- -$30.0M
- Net cash flow
- -$123.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $4.4B
- P/E ratio
- 24.7
- EPS (diluted)
- $1.64
- Shares outstanding
- 109.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 24, 2014
Indivior Pharmaceuticals, Inc. (INDV) Stock Price
- Profitable — net income of $210.0M in FY2025.
- Gross margin of 80.2%, net margin 16.9%.
- Trading near its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 24.7.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Indivior Pharmaceuticals, Inc..
Write a review
News about Indivior Pharmaceuticals, Inc.
News & sentiment via Polygon.io
Indivior Pharmaceuticals, Inc.: frequently asked questions
Is Indivior Pharmaceuticals, Inc. an American company?
Indivior Pharmaceuticals, Inc. is a US-based company headquartered in North Chesterfield, Virginia, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Indivior Pharmaceuticals, Inc. headquartered?
Indivior Pharmaceuticals, Inc. is headquartered in North Chesterfield, Virginia, United States.
Is Indivior Pharmaceuticals, Inc. publicly traded?
Yes — Indivior Pharmaceuticals, Inc. is a publicly traded company. Its stock trades under the ticker symbol INDV on the NASDAQ.
What does Indivior Pharmaceuticals, Inc. do?
Indivior Pharmaceuticals, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
